Top Markets
#1 Siacoin Siacoin +46.22%
#2 Official Trump Official Trump +31.38%
#3 Nockchain Nockchain +22.15%
#4 EXOD EXOD +18.93%
#5 Wrapped STX (Velar) Wrapped STX (Velar) +18.89%
#6 MowCat MowCat +18.59%
#7 Melania Meme Melania Meme +17.86%
#8 Power Ledger Power Ledger +17.78%
#9 Mubarak Mubarak +14.98%
#10 Unit Pump Unit Pump +14.81%
Coin of the day
Siacoin Siacoin
Settings
Language
ENGLISH
Currency
USD
Theme
Harpoon Therapeutics, Inc. Harpoon Therapeutics, Inc.

Harpoon Therapeutics, Inc.

HARP
Rank in Stocks #23352
Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States. The company's innovative Tri-specific T cell activating construct (TriTAC) platform forms the basis of its development pipeline. This includes HPN328, currently undergoing Phase I/II clinical trials for small cell lung cancer and tumors that express Delta-like canonical Notch ligand 3; HPN217, also in Phase I/II trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical evaluation for ovarian and pancreatic cancers, alongside other mesothelin-expressing tumors. Furthermore, Harpoon has a preclinical asset, HPN601, aimed at various solid tumor indications. The company has also established a discovery collaboration and licensing agreement with AbbVie Biotechnology Ltd. to develop and market products combining its unique TriTAC technology with soluble T cell receptors. Founded in 2015, Harpoon Therapeutics, Inc. is headquartered in South San Francisco, California.
Share Price
$23.01
Last synced: 2024-03-11
Market Cap
$74.80M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Harpoon Therapeutics, Inc. (HARP)

Category

Healthcare
Revenue for Harpoon Therapeutics, Inc. (HARP)
Revenue in Aug 2026 TTM: 0
According to Harpoon Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Harpoon Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH